Busulfan in hematopoietic stem cell transplant setting (Q37554387)

21 August 2017

1 reference

title

Busulfan in hematopoietic stem cell transplant setting (English)

1 reference

stem cell transplantation

21 August 2017

1 reference

ChEBI release 2020-05-28

ChEBI ID

28901

1 reference

1

1 reference

21 August 2017

Leona A Holmberg

2

1 reference

PubMed ID

19611402

21 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

Expert Opinion on Drug Metabolism & Toxicology

21 August 2017

1 reference

21 August 2017

5

1 reference

21 August 2017

957-969

1 reference

21 August 2017

8

1 reference

Plasma concentration monitoring of busulfan: does it improve clinical outcome?

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Optimal prevention of seizures induced by high-dose busulfan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Appropriate busulfan dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Population pharmacokinetics of intravenous busulfan in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Therapeutic drug monitoring opportunities in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Population pharmacokinetics of oral busulfan in young Japanese children before hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Comparison of basal glutathione S-transferase activities and of the influence of phenobarbital, butylated hydroxy-anisole or 5,5'-diphenylhydantoin on enzyme activity in male rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Lorazepam for seizure prophylaxis during high-dose busulfan administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia--the role of busulfan pharmacokinetics in determining outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Cellular and clinical pharmacology of fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Treosulfan-induced apoptosis in acute myeloid leukemia cells is accompanied by translocation of protein kinase C delta and enhanced by bryostatin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Addition of treosulfan to a nonmyeloablative conditioning regimen results in enhanced chimerism and immunologic tolerance in an experimental allogeneic bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903107764

10.1517/17425250903107764

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19611402